TCR² Therapeutics Presents Preclinical Data on IL-15 Enhanced TRuCs at AACR Virtual Special Conference on Tumor Immunology & Immunotherapy
October 05 2021 - 9:00AM
TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell
therapy company with a pipeline of novel T cell therapies for
patients suffering from cancer, today announced the e-poster
presentation of new preclinical data at the American Association
for Cancer Research (AACR) Virtual Special Conference on Tumor
Immunology and Immunotherapy, taking place October 5-6, 2021. The
e-poster titled “Expression of an IL-15 Receptor Fusion Protein
Enhances the Persistence of TRuC-T Cells” highlights preclinical
data on the Company’s proprietary mesothelin-directed T Cell
Receptor Fusion Construct (TRuC®) T cells that express IL-15-based
enhancements as a strategy for improving T cell persistence. The
co-expression of these IL-15 enhancements enriched for naïve and
central memory T cells, upregulated the stemness-associated
transcription factor TCF-1 and increased TRuC-T cell proliferation
upon repeated stimulation with mesothelin-expressing cancer cell
lines. In addition, IL-15 promoted the survival of TRuC-T cells in
the absence of T cell receptor (TCR) or exogenous cytokine
stimulation. In a mesothelioma xenograft mouse model, IL-15
co-expression resulted in a higher number of TRuC-T cells in the
tumor and significantly increased their persistence in peripheral
blood. The administration of a single dose of IL-15 enhanced TRuC-T
cells cleared tumors in all mice and fully protected them from
tumor rechallenge.
“We are excited to announce preclinical data
from our latest platform enhancement, TRuC-T cells expressing a
membrane-bound IL-15. These preclinical in vitro and in vivo data
support our belief that we can further design and optimize our
TRuC-T cells to persist in the hostile tumor microenvironment and
potentially increase persistence for improved efficacy against
solid tumors where needed in certain cancer indications,” said
Robert Hofmeister, Ph.D., Chief Scientific Officer of TCR2
Therapeutics. “We continue to innovate for maximum patient benefit
and look forward to discussing in-depth our overall enhancements
strategy and broader pipeline, including allogeneic TRuCs, novel
targets and TRuC Tregs, at our upcoming R&D Day on October
20.”
The e-poster and poster video presented at AACR are available in
the Presentations section of the Investors page of the Company’s
website at investors.tcr2.com.
About TCR2
Therapeutics
TCR2 Therapeutics Inc. is a
clinical-stage cell therapy company developing a pipeline of novel
T cell therapies for patients suffering from
cancer. TCR2’s proprietary T cell receptor (TCR) Fusion
Construct T cells (TRuC®-T cells) specifically recognize and
kill cancer cells by harnessing signaling from the entire TCR,
independent of human leukocyte antigens (HLA). In preclinical
studies, TRuC-T cells have demonstrated superior anti-tumor
activity compared to chimeric antigen receptor T cells (CAR-T
cells), while secreting lower levels of cytokine release. The
Company’s lead TRuC-T cell product candidate targeting solid
tumors, gavocabtagene autoleucel (“gavo-cel”), is currently being
studied in a Phase 1/2 clinical trial to treat patients with
mesothelin-positive non-small cell lung cancer (NSCLC), ovarian
cancer, malignant pleural/peritoneal mesothelioma, and
cholangiocarcinoma. The Company’s lead TRuC-T cell product
candidate targeting hematological malignancies, TC-110, is
currently being studied in a Phase 1/2 clinical trial to treat
patients with CD19-positive adult acute lymphoblastic leukemia
(aALL) and with aggressive or indolent non-Hodgkin lymphoma (NHL).
For more information about TCR2, please
visit www.tcr2.com.
Forward-looking Statements
This press release contains forward-looking
statements and information within the meaning of the Private
Securities Litigation Reform Act of 1995 and other federal
securities laws. The use of words such as "may," "will," "could",
"should," "expects," "intends," "plans," "anticipates," "believes,"
"estimates," "predicts," "projects," "seeks," "endeavor,"
"potential," "continue" or the negative of such words or other
similar expressions can be used to identify forward-looking
statements. These forward-looking statements include, but are not
limited to, express or implied statements regarding the therapeutic
potential of gavo-cel , timing of clinical data releases, future
clinical development plans, the development of the Company’s TRuC-T
cells, their potential characteristics, applications and clinical
utility, and the potential therapeutic applications of the
Company’s TRuC-T cell platform.
The expressed or implied forward-looking
statements included in this press release are only predictions and
are subject to a number of risks, uncertainties and assumptions,
including, without limitation: uncertainties inherent in clinical
studies and in the availability and timing of data from ongoing
clinical studies; whether interim results from a clinical trial
will be predictive of the final results of the trial; whether
results from preclinical studies or earlier clinical studies will
be predictive of the results of future trials; the expected timing
of submissions for regulatory approval or review by governmental
authorities, including review under accelerated approval processes;
orphan drug designation eligibility; regulatory approvals to
conduct trials or to market products; TCR2’s ability to maintain
sufficient manufacturing capabilities to support its research,
development and commercialization efforts, whether TCR2's cash
resources will be sufficient to fund TCR2's foreseeable and
unforeseeable operating expenses and capital expenditure
requirements, the impact of the COVID-19 pandemic on TCR2’s ongoing
operations; and other risks set forth under the caption "Risk
Factors" in TCR2’s most recent Annual Report on Form 10-K, most
recent Quarterly Report on Form 10-Q and its other filings with
the Securities and Exchange Commission. In light of these
risks, uncertainties and assumptions, the forward-looking events
and circumstances discussed in this press release may not occur and
actual results could differ materially and adversely from those
anticipated or implied in the forward-looking statements. You
should not rely upon forward-looking statements as predictions of
future events. Although TCR2 believes that the expectations
reflected in the forward-looking statements are reasonable, it
cannot guarantee that the future results, levels of activity,
performance or events and circumstances reflected in the
forward-looking statements will be achieved or occur.
Moreover, except as required by law, neither
TCR2 nor any other person assumes responsibility for the
accuracy and completeness of the forward-looking statements
included in this press release. Any forward-looking statement
included in this press release speaks only as of the date on which
it was made. We undertake no obligation to publicly update or
revise any forward-looking statement, whether as a result of new
information, future events or otherwise, except as required by
law.
Investor and Media Contact:
Carl MauchDirector, Investor Relations and
Corporate CommunicationsTCR2 Therapeutics Inc.(617)
949-5667carl.mauch@tcr2.com
TCR2 Therapeutics (NASDAQ:TCRR)
Historical Stock Chart
From Jun 2024 to Jul 2024
TCR2 Therapeutics (NASDAQ:TCRR)
Historical Stock Chart
From Jul 2023 to Jul 2024